Fenfluramine
Clinical data | |
---|---|
Trade names | Seizures: Fintepla Appetite suppressant: Pondimin, Ponderax, Ponderal, others |
Other names | ZX008; 3-Trifluoromethyl-N-ethylamphetamine |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a620045 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 13–30 hours[5] |
Identifiers | |
| |
JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
Fenfluramine, sold under the brand name Fintepla, is a
Fenfluramine was developed in the early 1960s and was first introduced for medical use as an appetite suppressant in
Medical uses
Seizures
Fenfluramine is indicated for the treatment of seizures associated with Dravet syndrome and Lennox–Gastaut syndrome in people age two and older.[6][7][3]
Dravet syndrome is a life-threatening, rare and chronic form of epilepsy.[7] It is often characterized by severe and unrelenting seizures despite medical treatment.[7]
Obesity
Fenfluramine was formerly used as an
Adverse effects
The most common adverse reactions in people with seizures include decreased appetite; drowsiness, sedation and lethargy; diarrhea; constipation; abnormal echocardiogram; fatigue or lack of energy; ataxia (lack of coordination), balance disorder, gait disturbance (trouble with walking); increased blood pressure; drooling, salivary hypersecretion (saliva overproduction); pyrexia (fever); upper respiratory tract infection; vomiting; decreased weight; risk of falls; and status epilepticus.[7]
The U.S. Food and Drug Administration (FDA) fenfluramine labeling includes a boxed warning stating the drug is associated with valvular heart disease (VHD) and pulmonary arterial hypertension (PAH).[7] Because of the risks of VHD and PAH, fenfluramine is available only through a restricted drug distribution program, under a risk evaluation and mitigation strategy (REMS).[7] The fenfluramine REMS requires health care professionals who prescribe fenfluramine and pharmacies that dispense fenfluramine to be specially certified in the fenfluramine REMS and that patients be enrolled in the REMS.[7] As part of the REMS requirements, prescribers and patients must adhere to the required cardiac monitoring with echocardiograms to receive fenfluramine.[7]
At higher therapeutic doses,
There have been reports associating chronic fenfluramine treatment with
Heart valve disease
The distinctive valvular abnormality seen with fenfluramine is a thickening of the leaflet and chordae tendineae. One mechanism used to explain this phenomenon involves heart valve serotonin receptors, which are thought to help regulate growth. Since fenfluramine and its active metabolite norfenfluramine stimulate serotonin receptors, this may have led to the valvular abnormalities found in patients using fenfluramine. In particular norfenfluramine is a potent inhibitor of the re-uptake of 5-HT into nerve terminals.[22] Fenfluramine and its active metabolite norfenfluramine affect the 5-HT2B receptors, which are plentiful in human cardiac valves. The suggested mechanism by which fenfluramine causes damage is through over or inappropriate stimulation of these receptors leading to inappropriate valve cell division. Supporting this idea is the fact that this valve abnormality has also occurred in patients using other drugs that act on 5-HT2B receptors.[23][24]
According to a study of 5,743 former users conducted by a plaintiff's expert cardiologist, damage to the heart valve continued long after stopping the medication.[25] Of the users tested, 20% of women, and 12% of men were affected. For all ex-users, there was a 7-fold increase of chances of needing surgery for faulty heart valves caused by the drug.[25]
Overdose
In
Pharmacology
Pharmacodynamics
Fenfluramine acts primarily as a
The combination of fenfluramine with phentermine, a norepinephrine–dopamine releasing agent acting primarily on norepinephrine, results in a well-balanced serotonin–norepinephrine releasing agent with weaker effects of dopamine release.[27][28]
Drug | NE | DA | 5-HT | Type | Ref |
---|---|---|---|---|---|
Fenfluramine | 739 | >10,000 | 79.3–108 | SRA | [32][27][28] |
D-Fenfluramine | 302 | >10,000 | 51.7 | SNRA | [32][27] |
L-Fenfluramine |
>10,000 | >10,000 | 147 | SRA | [27][33] |
Norfenfluramine | 168–170 | 1,900–1,925 | 104 | SNRA | [27][28] |
Phentermine | 39.4 | 262 | 3,511 | NDRA | [32] |
Fenfluramine was identified as a
Pharmacokinetics
The
Chemistry
Fenfluramine is a substituted amphetamine and is also known as 3-trifluoromethyl-N-ethylamphetamine.[8] It is a racemic mixture of two enantiomers, dexfenfluramine and levofenfluramine.[8] Some analogues of fenfluramine include norfenfluramine, benfluorex, flucetorex, and fludorex.
History
Fenfluramine was developed in the early 1960s and was introduced in France in 1963.[8] Approximately 50 million Europeans were treated with fenfluramine for appetite suppression between 1963 and 1996.[8] Fenfluramine was approved in the United States in 1973.[8] The combination of fenfluramine and phentermine was proposed in 1984.[8] Approximately 5 million people in the United States were given fenfluramine or dexfenfluramine with or without phentermine between 1996 and 1998.[8]
In the early 1990s, French researchers reported an association of fenfluramine with primary
Fenfluramine was an appetite suppressant which was used to treat obesity.[8] It was used both on its own and, in combination with phentermine, as part of the anti-obesity medication Fen-Phen.[8]
In June 2020, fenfluramine was approved for medical use in the United States with an indication to treat Dravet syndrome.[7][37]
The effectiveness of fenfluramine for the treatment of seizures associated with Dravet syndrome was demonstrated in two clinical studies in 202 subjects between ages two and eighteen.[7] The studies measured the change from baseline in the frequency of convulsive seizures.[7] In both studies, subjects treated with fenfluramine had significantly greater reductions in the frequency of convulsive seizures during the trials than subjects who received placebo (inactive treatment).[7] These reductions were seen within 3–4 weeks, and remained generally consistent over the 14- to 15-week treatment periods.[7]
The U.S. Food and Drug Administration (FDA) granted the application for fenfluramine priority review and orphan drug designations.[7][38][39] The FDA granted approval of Fintepla to Zogenix, Inc.[7]
On 15 October 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Fintepla, intended for the treatment of seizures associated with Dravet syndrome.[40] Fenfluramine was approved for medical use in the European Union in December 2020.[3]
Society and culture
Legal status
Fenfluramine is a prescription medication in the US. Fenfluramine was removed from Schedule IV of the Controlled Substances Act in December 2022.[41]
Recreational use
Unlike various other amphetamine derivatives, fenfluramine is reported to be
Indirect (via induction of serotonin release) and/or direct activation of the 5-HT2A receptor would be expected to be responsible for the psychedelic effects of the drug at sufficient doses.References
- FDA. Retrieved 22 Oct 2023.
- ^ Anvisa (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.
- ^ a b c d e "Fintepla EPAR". European Medicines Agency. 13 October 2020. Retrieved 8 January 2021.
- ^ "Fintepla Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ ISBN 978-0-7817-2845-4. Archivedfrom the original on 2018-05-09.
- ^ a b c d "FINTEPLA (fenfluramine) oral solution" (PDF). Zogenix Inc. U.S. Food and Drug Administration. March 2022.
- ^ a b c d e f g h i j k l m n o p q r "FDA Approves New Therapy for Dravet Syndrome". U.S. Food and Drug Administration (FDA) (Press release). 25 June 2020. Retrieved 25 June 2020. This article incorporates text from this source, which is in the public domain.
- ^ ISBN 978-1-118-10605-1. Archivedfrom the original on 9 May 2018.
- ^ PMID 33895186.
- ISBN 978-3-88763-075-1.
- ^ Kolata, Gina (September 23, 1997). "How Fen-Phen, A Diet 'Miracle,' Rose and Fell". New York Times. NY, NY, USA.
- S2CID 84029575.
- ^ PMID 34445144.
- ^ S2CID 212643918.
- S2CID 52889559.
- ^ S2CID 46466276.
- ^ "Schedules of Controlled Substances: Removal of Fenfluramine From Control". U.S. Federal Register. 23 December 2022.
- ^ ISBN 978-0-913875-27-8.
- ISBN 978-0-08-047508-0.
- ]
- ISBN 978-0-08-087817-1.
- S2CID 23374227.
- PMID 17202450.
- PMID 19505264.
- ^ PMID 18990200.
- ISBN 978-1-58562-744-8.
- ^ S2CID 21164342.
- ^ S2CID 839426.
- ^ Nestler EJ (2001). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. McGraw-Hill.
- ISBN 978-0-444-53235-0.
- PMID 10617681.
- ^ S2CID 15573624.
- PMID 12163129.
- PMID 9271479.
- ^ "FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen)". U.S. Food and Drug Administration. 15 September 1997. Archived from the original on 19 July 2013.
- ^ "Drugs banned in India". Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India. Archived from the original on 2015-02-21. Retrieved 2013-09-17.
- ^ "FDA Approves FINTEPLA (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome" (Press release). Zogenix Inc. 25 June 2020. Retrieved 25 June 2020 – via GlobeNewswire.
- ^ "Fenfluramine Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 25 June 2020.
- ^ "Fenfluramine Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 25 June 2020.
- ^ "Fintepla: Pending EC decision". European Medicines Agency (EMA). 16 October 2020. Archived from the original on 21 October 2020. Retrieved 16 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- DEA. December 23, 2022. Retrieved July 14, 2023.
- ^ ISBN 978-0-7506-7313-6.
- ^ Competitive problems in the drug industry: hearings before Subcommittee on Monopoly and Anticompetitive Activities of the Select Committee on Small Business, United States Senate, Ninetieth Congress, first session. U.S. Government Printing Office. 1976. pp. 2–.
{{cite book}}
:|work=
ignored (help) - ^ ISBN 978-3-642-66709-1.
- ISBN 978-3-642-66709-1.
Further reading
- Gustafsson BI, Tømmerås K, Nordrum I, Loennechen JP, Brunsvik A, Solligård E, Fossmark R, Bakke I, Syversen U, Waldum H (March 2005). "Long-term serotonin administration induces heart valve disease in rats". Circulation. 111 (12): 1517–22. PMID 15781732.
- Welch JT, Lim DS (November 2007). "The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine". Bioorganic & Medicinal Chemistry. 15 (21): 6659–6666. PMID 17765553.